Turning Point Therapeutics (TPTX) Stock Analysis

What Turning Point Therapeutics does

Turning Point Therapeutics is a biopharmaceutical firm specializing in precision oncology, currently in the clinical development stage. The company is dedicated to discovering and advancing targeted therapies that address the underlying genetic causes of cancer. They have developed a portfolio of innovative tyrosine kinase inhibitors (TKIs) designed to treat cancer patients, including those who have not yet received TKI treatment and those who have previously been treated with TKIs. Their flagship experimental compound, repotrectinib, is currently undergoing evaluation in the Phase 1/2 TRIDENT-1 clinical study. This trial is aimed at individuals with advanced non-small-cell lung cancer (NSCLC) characterized by ROS1 positivity, as well as those with advanced solid tumors exhibiting ROS1 and NTRK mutations. The company's developmental pipeline further includes TPX-0022, a MET/SRC/CSF1R inhibitor, which is in a Phase 1 SHIELD-1 trial for advanced solid tumors carrying MET genetic abnormalities. Additionally, TPX-0046, a RET inhibitor, is progressing through its Phase 1/2 SWORD-1 clinical trial for advanced solid tumors with RET genetic variations. Finally, TPX-0131, an ALK inhibitor, is being investigated in the Phase 1/2 FORGE-1 study for patients with advanced or metastatic ALK-positive NSCLC who have previously undergone TKI therapy. Established in San Diego, California, in 2013, Turning Point Therapeutics became a subsidiary of Bristol-Myers Squibb Company on August 15, 2022.

Key metrics

ETFs linked to TPTX

Broad-market and Healthcare sector ETFs an investor holding Turning Point Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TPTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Turning Point Therapeutics?

Turning Point Therapeutics trades under the ticker TPTX on NASDAQ.

Which exchange is TPTX listed on?

TPTX is listed on NASDAQ.

What sector does Turning Point Therapeutics operate in?

Turning Point Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TPTX in a portfolio?

PortView shows TPTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.